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Abstract
Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment
of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high
therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a
serious adverse effect. Furthermore, drug cessation sometimes induces rebound disease activity of unknown etiology. Here
we investigated whether binding of this adhesion-blocking antibody to T lymphocytes could modulate their phenotype by
direct induction of intracellular signaling events. Primary CD4+ T lymphocytes either from healthy donors and treated with
natalizumab in vitro or from MS patients receiving their very first dose of natalizumab were analyzed. Natalizumab induced
a mild upregulation of IL-2, IFN-c and IL-17 expression in activated primary human CD4+ T cells propagated ex vivo from
healthy donors, consistent with a pro-inflammatory costimulatory effect on lymphokine expression. Along with this,
natalizumab binding triggered rapid MAPK/ERK phosphorylation. Furthermore, it decreased CD49d surface expression on
effector cells within a few hours. Sustained CD49d downregulation could be attributed to integrin internalization and
degradation. Importantly, also CD4+ T cells from some MS patients receiving their very first dose of natalizumab produced
more IL-2, IFN-c and IL-17 already 24 h after infusion. Together these data indicate that in addition to its adhesion-blocking
mode of action natalizumab possesses mild direct signaling capacities, which can support a pro-inflammatory phenotype of
peripheral blood T lymphocytes. This might explain why a rebound of disease activity or IRIS is observed in some MS
patients after natalizumab cessation.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the CNS [1]. It may take a relapsing-remitting or a
chronic progressive clinical course. The immigration of activated
T lymphocytes into the CNS is fundamental to its pathogenesis
[2]. During disease development, CD4+ T cells encounter
environmental triggers of unknown kind in the periphery. This,
in a widely accepted view, leads to activation of CNS antigen
specific CD4+ T cells in genetically susceptible individuals. These
autoreactive T cells then cross the blood-brain barrier (BBB) as
effector T helper (Th) cells and initiate a chronic autoimmune
disease [3].
Th1 cells, as defined by IFN-c and TNF-a production, were
found to be the predominant subpopulation of T lymphocytes in
the CNS and the peripheral blood of MS patients [4,5]. Later on,
a newly defined lineage of T cells, named Th17 according to their
signature lymphokine IL-17, could be linked to the development of
experimental autoimmune encephalomyelitis (EAE), an animal
model of MS [6]. Several recent publications considered Th17
cells, which additionally adopt the production of IFN-c, as disease-
promoting cells in EAE and also in MS [7].
Effector lymphocytes express elevated levels of adhesion
molecules, enabling them to leave the vascular bed across the
endothelium. More specifically, their firm arrest to endothelial
cells is mediated by integrins. Integrin receptors are composed of
non-covalently linked a- and b-chains. A special feature of
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integrins is their ability of bi-directional signaling [8]. The ‘inside-
out’ signal is often evoked by chemoattractants and chemokines,
but also by the T cell receptor (TCR), and induces integrin
clustering as well as conformational changes, thereby enhancing
avidity and/or affinity of an integrin receptor to its ligand [9].
Subsequent binding of the ligand initiates ‘outside-in’ signaling,
which connects to growth factor pathways through protein-protein
interactions [10].
The integrin a-4 (CD49d) is known to dimerize with either
integrin b-1 (CD29) or b-7. These integrin subunits are expressed
by ITGA4, ITGB1 and ITGB7, respectively. The a-4/b-1
heterodimer – also termed VLA-4– allows firm arrest of
lymphocytes to the vessel wall through engagement of its
endothelial counterpart VCAM-1 (CD106). VCAM-1 is upregu-
lated on brain microvascular endothelial cells in inflammatory
CNS lesions of patients with MS [11,12]. VLA-4 is strongly
expressed on activated leukocytes including myelin basic protein
(MBP) specific CD4+ T cells, which may trigger EAE but – such as
any other antigen-specific T cell – are of unknown relevance to the
human disease [13]. VLA-4 was found to be their main homing
molecule for extravasation across the blood-brain barrier (BBB)
into the inflamed CNS of EAE mice [14].
Natalizumab is a humanized monoclonal IgG4k antibody
directed against the human integrin a-4 subunit of VLA-4 and was
generated to physically interfere with lymphocyte extravasation
across the BBB in patients with MS, after the central pathogenic
relevance of VLA-4 in EAE had been discovered [15]. In patients
with relapsing-remitting MS (RRMS), natalizumab reduced the
annualized relapse rate by 68% compared to placebo, caused a
42% reduction of sustained disability progression over two years,
and had a strong therapeutic effect on MRI disease activity [16]. It
is approved for the treatment of patients with RRMS in Europe
and the US. 104,300 patients worldwide had received the drug
since its approval until June 30th, 2012. Natalizumab is well
tolerated by most MS patients. However, its use is limited by the
rare occurrence of progressive multifocal leukoencephalopathy
(PML), a life-threatening opportunistic brain infection by JC virus
[17]. As of October 3rd 2012, natalizumab-associated PML
affected 298 individuals, corresponding to,2.71 in 1,000 patients,
63 (21%) of whom had died until that time point. The risk of PML
independently increases with treatment duration and immuno-
suppressive pretreatment. Furthermore, it is determined by the
JCV serostatus, which indicates a potential latent JCV infection
along with a risk of PML when positive, while the risk is ,1:5.000
when the test is negative [17,18].
To rapidly remove natalizumab in case of PML, patients receive
plasma exchange or immunoabsorption to hasten immune
reconstitution. However, they regularly develop exuberant CNS
inflammatory disease activity a few weeks later, termed immune
reconstitution inflammatory syndrome (IRIS) or more specifically
PML-IRIS [19,20,21,22]. Without PML, MS disease activity after
natalizumab cessation most often returns to pretreatment levels
within a few months [23]. However, cases of rebound disease
activity were observed by a number of investigators and in our
own clinical experience [24,25,26,27]. This occasional post-
treatment overshoot of CNS inflammation might partially be
due to an increased percentage of pro-inflammatory CD4+ and
CD8+ T cells, as observed in the peripheral blood during
treatment with natalizumab over six months and longer
[28,29,30]. Following natalizumab cessation, inflammatory acti-
vated lymphocytes may then enter the CNS, which is no longer
protected by the drug.
The reason for the occurrence of peripheral pro-inflammatory
T lymphocytes during natalizumab treatment is unknown.
Therefore, we decided to explore the capability of this anti-
integrin a-4 antibody to modulate the phenotype of T lymphocytes
by direct induction of intracellular signaling. And indeed,
natalizumab, designed to block CD49d-mediated immune cell
extravasation, was found to induce overall mild ‘outside-in’ signals
in activated T lymphocytes along with an increased expression of
pro-inflammatory cytokines. In line with inter-individual differ-
ences with respect to rebound disease and PML-IRIS, not all T
cells were equally responsive. Therefore, natalizumab signals
directly and – dependent on the immunological situation of
individual patients with MS – can serve as a pro-inflammatory
costimulus for T cell receptor-activated cells.
Materials and Methods
Subjects
All experiments involving MS patients were approved by the
Ethics Committee of the Faculty of Medicine at the University of
Wu¨rzburg. Written informed consent was obtained from all 9
patients prior to collection of blood samples. All of them had
RRMS according to the 2005 revision of the McDonald diagnostic
criteria [31]. Eight patients were female, one was male. Median
age at study inclusion was 32 (range 23–46) years. Median disease
duration was 7 (range 2–15) years. Median Expanded Disability
Status Scale (EDSS) at study inclusion was 3.0 (range 1.5–4.0). All
patients had experienced break-through disease activity on
secondary prophylactic treatment with an approved interferon b
preparation or glatiramer acetate before starting natalizumab
therapy. Three of 9 patients had received immunosuppressive
treatment with mitoxantrone and/or azathioprine in the past.
None of the patients had received corticosteroid treatment within
3 weeks before study inclusion and none had an acute relapse.
Blood was taken immediately before the very first infusion of
300 mg natalizumab (TysabriH, Biogen Idec/Elan, Ismaning,
Germany) intravenously in a routine clinical setting and 24 h after
infusion.
Blood from healthy donors of random age and gender was
obtained after written informed consent in accordance with the
Declaration of Helsinki, under a protocol that had received
Institutional Review Board approval from the Ethics Committee
of the Faculty of Medicine at the University of Wu¨rzburg. In
addition, PBL generated during thrombocytapheresis of blood
from healthy donors were kindly provided by the local Depart-
ment of Transfusion Medicine. Since these blood samples were
offered anonymously, the Ethics Committee of the Faculty of
Medicine at the University of Wu¨rzburg gives a general approval.
Cell Isolation, Cultivation and Stimulation
PBMC were isolated from EDTA blood samples via centrifu-
gation in BiocollH separating solution (Biochrom, Berlin, Ger-
many). CD4+ T lymphocytes were enriched by positive selection
using a MACS human CD4 microbeads isolation kit (Miltenyi
Biotech, Bergisch Gladbach, Germany). Purity of the CD4+
population was typically .85% up to 95%.
For microarray gene expression profiling, 3.06105 CD4+ T cells
were placed in 25 ml CTL medium containing 30 Gy irradiated
PBMC (2.56107), 60 Gy irradiated T2 feeder cells (5.06106), and
OKT-3 (30 ng/ml) for 3 days [32]. Recombinant IL-2 (50 U/ml)
was added on days 1, 3, 7 and 10. After this expansion and
synchronization, cells were reseeded either in the absence or
presence of natalizumab (30 mg/ml) on day 13. The natalizumab
concentration was chosen based on mean average steady-state
through serum levels of 23 to 29 mg/ml and mean peak serum
levels of 110652 (SD) mg/ml in MS patients receiving 300 mg
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natalizumab every 28 days, as reported in the prescribing
information. Natalizumab (TysabriH) for in vitro experiments was
purchased from our local pharmacy at the University Hospital
Wu¨rzburg. Ten days after reseeding, cells were restimulated with
T/I (10 ng/ml TPA, Sigma-Aldrich, Hamburg, Germany; 2 mM
ionomycin, Life Technologies, Darmstadt, Germany) for 8 h and
fresh natalizumab was added in order to recall the developed
program and induce cytokine expression. Subsequently, cells were
pelleted and resuspended in 1 ml TrizolH (Life Technologies).
Except for microarray experiments, PBMC and CD4+ T
lymphocytes (1–56106 cells/ml) were cultured in complete X-
VIVO15 medium, supplemented with 10% heat-inactivated,
pooled human AB serum and 100 U/ml penicillin-streptomycin
(all from Life Technologies). Jurkat cells (56106 cells/ml) were
kept in complete RPMI1640 medium, containing 5% heat-
inactivated FCS. Cells were stimulated for the indicated times
(2, 4, 8, 24, 48, 72 h): 1 mg/ml staphylococcus enterotoxin B (SEB,
Toxin Technology, Sarasota, FL), anti-CD3/28-DynabeadsH (Life
Technologies) or plate-bound anti-CD3/28 mAb (both 5 mg/ml,
BD Biosciences, Heidelberg, Germany), T/I (10 ng/ml/2 mM) in
the absence or presence of natalizumab (30 mg/ml), controlled by
IgG4 (BD Biosciences or Sigma Aldrich) or HP2/1 (Abcam,
Cambridge, UK; Abnoby, Heidelberg, Germany; or Beckman
Coulter, Krefeld, Germany). For intracellular FACS stainings
1 mg/ml brefeldin A or brefeldin A plus 1.34 mg/ml monensin (for
IL-17 and IFN-c was added for the last 8–12 h.
Gene Expression Arrays
Gene expression profiling was performed with HG U133 plus
2.0 gene expression arrays (Affymetrix) following the Affymetrix
expression analysis technical manual (www.affymetrix.com). Data
were normalized by the Gene Chip Operating Software (GCOS)
from Affymetrix. The intensity values of each donor were
averaged in groups and the mean values of the natalizumab
samples subtracted from those without natalizumab treatment.
Sorted intensity values of stimulated and non-stimulated samples
in an ascending and descending manner determined genes with
the most prominent and at least two-fold differences in expression.
For pathway annotation (at least 0.5-fold [log2] change) a two-
tailed t-test and gene set enrichment analysis (GSEA) (http://
www.broad.mit.edu/gsea) was performed. For cluster analysis and
visualization of the data the Cluster and TreeView software
packages (http://rana.lbl.gov/EisenSoftware.htm, M. Eisen, Ber-
keley, CA) were used.
FACS Staining
Cells were harvested, washed in PBS and FACS buffer (PBS
containing 0.1% BSA), blocked with Fc receptor blocking reagent
(BD Biosciences) for 10 min at room temperature (RT) and rinsed
with FACS buffer. Surface staining was performed using anti-
human CD4-FITC and anti-human CD49d-PE (all BD Biosci-
ences), for 30 min at RT, and fixation with 2% paraformaldehyde
(PFA) in PBS, for 20 min at RT. For intracellular staining cells
were incubated in permeabilization buffer (FACS buffer contain-
ing 0.1% saponin), for 10 min at RT, pelleted, resuspended in a
small volume of permeabilization buffer, and stained with anti-
IFN-c-FITC, anti-IL-17-APC or anti-IL-2-APC (all Miltenyi
Biotech), for 90 min at 4uC. Washed samples were measured on
the FACS LSRII flow cytometer (BD Biosciences) and analyzed
using FlowJo software (Tree Star, Ashland, OR, http://www.
flowjo.com).
Quantitative RT-PCR
Total RNA from human primary CD4+ T cells was purified
using TrizolH (Life Technologies), and cDNA was accomplished
by the iScript cDNA synthesis kit (BioRad, Hercules, CA).
Quantitative RT-PCR (qRT-PCR) was performed by using an
ABI 7000 RT-PCR instrument (Applied Biosystems, Carlsbad,
CA). All primers were TaqManH probes from Applied Biosystems
and used according to the manufacturer’s standard protocols.
Normalization for each sample was achieved by using the formula:
DCT=CT(target gene) – CT(B2M). Relative expression was calculat-
ed with the formula: 2–DCT.
Figure 1. Top ten genes with natalizumab-driven differential expression levels. (A) List of genes that were influenced the most by
natalizumab in CD4+ T cells, which were restimulated for 8 h. (B) List of genes that were influenced the most by natalizumab in CD4+ T cells, which
were not restimulated.
doi:10.1371/journal.pone.0052208.g001
Table 1. List of ‘‘Top Ten Pathways’’ that were shown to be enriched in the group of natalizumab-treated CD4+ T cells.
Gene set
# genes in
gene set (K)
# genes in
overlap (k) k/K P value
LEE_TCELLS3_UP 106 16 0.159 7.76E-06
MOREAUX_TACI_HI_VS_LOW_UP 422 37 0.0877 1.52E-05
GOLDRATH_CELLCYCLE 34 8 0.2353 6.11E-05
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 257 24 0.0934 1.61E-04
NUCLEAR_RECEPTORS 40 8 0.2 2.00E-04
STEMPATHWAY 15 5 0.3333 2.68E-04
IDX_TSA_UP_CLUSTER3 90 12 0.1333 3.10E-04
CDC25PATHWAY 9 4 0.4444 3.29E-04
DOX_RESIST_GASTRIC_UP 44 8 0.1818 3.88E-04
GAMMA-UV_FIBRO_UP 35 7 0.2 4.92E-04
Genes were annotated to pathways (C2) using GSEA (Gene Set Enrichment Analysis) database, which showed at least a 0.5 fold [log2] stronger expression in the group
of natalizumab-treated CD4+ T cells than in the group of natalizumab-untreated cells according to the respective mean values of three biological replicates.
doi:10.1371/journal.pone.0052208.t001
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Immunoblot
Whole cellular protein lysates were made from 26107 Jurkat or
CD4+ T cells using RIPA buffer and the snap-freezenthaw
method. Nuclear and cytosolic protein extracts were generated
using the ProteoJETH Cytoplasmic and Nuclear Protein Extrac-
tion Kit (Fermentas Life Sciences, St. Leon-Rot, Germany). An
equal amount of total protein was fractionated by 12% SDS-
PAGE and electroblotted onto nitrocellulose membrane. For
detection, anti-JNK, anti-pJNK, anti-ERK, anti-pERK and anti-
NFATc1 antibodies (all from Santa Cruz Biotechnology, Heidel-
berg, Germany), with corresponding anti-mouse or anti-rabbit
peroxidase-coupled secondary antibodies (Sigma Aldrich) were
used with an enhanced chemiluminescence system (Pierce, Rock-
ford, IL). To analyze CD49d protein levels in cell culture
supernatants, proteins were first concentrated by centrifugation
of 300 ml per stimulation condition supernatant through Microcon
YM-10 centrifugal filter devices (Millipore, Schwalbach/Ts.,
Germany). The recovered proteins were fractionated by 8%
SDS-PAGE and electroblotted onto nitrocellulose membrane. For
detection, two different mAbs against the extracellular domain of
CD49d (clone L25, BD Biosciences; clone HP2/1, Beckman
Coulter) were used with an anti-mouse peroxidase-coupled
secondary antibody (Jackson ImmunoResearch via Dianova,
Hamburg, Germany) along with an enhanced chemoluminescence
system (BD Biosciences).
Cytokine Measurement
PBMC from MS patients were isolated, resuspended at a total of
56106/ml cells and stimulated with plate-bound anti-CD3/28
(both BD Biosciences) in a 24-well tissue culture plate. Superna-
tants were collected after 48 h and cytokine measurement of
human IFN-c, IL-2, IL-10, IL-4, IL-21, IL-12/IL-23 p40 and IL-
17 was performed using a cytometric bead array (CBA) kit (BD
Biosciences). The mixtures were incubated for 3 h; beads were
washed and analyzed using flow cytometry (FACS CantoII, BD
Biosciences). Cytokine concentration (pg/ml) was calculated using
CBA software.
Immunocytochemistry
Following stimulation as indicated, 56104 PBMC per stimula-
tion condition were transferred to microscope slides, using a
standard cytospin protocol. Cells were fixed with 3.7% PFA for
10 min and permeabilized with 0.1% Triton X-100 for 5 min at
RT, washed two times with phosphate-buffered saline and blocked
in PBS containing 5% BSA for 1 h at RT. Subsequently, a
primary mouse mAb against CD49d (clone L25) in PBS
containing 1% BSA was incubated at 4uC overnight. Then, a
Cy3-coupled anti-mouse secondary antibody (Jackson ImmunoR-
esearch) was incubated for 1 h at RT. Nuclei were counterstained
with DAPI. Finally, an antifading agent comprised of Mowiol 4–
88 (Calbiochem), glycerole and Dabco (Sigma Aldrich) in 0.2 M
Tris HCl was added. Negative controls were performed by
staining with an isotype-matched IgG2b control antibody (BD
Biosciences). The stainings were analyzed by confocal laser
scanning microscopy (Leica TCS SP2 equipment, objective lense;
HeX PL APO, 406/1.25–0.75) and LCS software (Leica).
ELISA
Total protein levels of matrix metalloproteinases MMP-2 and
MMP-9 in culture supernatants of 16107 PBMC in 2 ml complete
X-VIVO15 medium as detailed above were measured using
commercial ELISA kits (R&D, Wiesbaden-Nordenstadt, Ger-
many) according to the instructions of the manufacturer. Both
MMP-2 and MMP-9 were detectable in all supernatants. All
samples were analyzed in duplicates. Mean intraassay reproduc-
ibility was 7.4% for MMP-2 and 6.2% for MMP-9.
Statistical Analysis
Except for pathway annotation of microarray data, where two-
tailed t tests were employed (see above), non-parametric tests were
used throughout the study. For comparison of two conditions, a
two-tailed Wilcoxon matched-pairs signed rank test or a two-tailed
Mann-Whitney test were employed as appropriate. For compar-
ison of more than two time points, Bonferroni adjustment was
applied, when indicated. Alternatively, a two-tailed Friedman test
or a two-tailed Kruskal-Wallis test were performed, which both
were followed by Dunn’s multiple comparisons test, if p values
were ,0.05. For correlation analysis, Spearman tests were used. A
p value,0.05 was considered as statistically significant. GraphPad
PRISM 5 software (La Jolla, CA) was used for all analyses.
Results
The Blocking Antibody Natalizumab Signals
In order to detect any possible signaling via natalizumab we
performed an unbiased screen by gene expression profiling using
the HG U133 plus 2.0 gene expression arrays (Affymetrix). RNA
Table 2. Natalizumab supports expression of cytokines and
their receptors.
IL2 Interleukin 2
IL4 Interleukin 4
IL9 Interleukin 9
IL3 Interleukin 3 (colony-stimulating factor, multiple)
CSF1 Colony stimulating factor 1 (macrophage)
LTB Lymphotoxin beta (TNF superfamily, member 3)
LTA Lymphotoxin alpha (TNF superfamily, member 1)
CXCL5 Chemokine (C-X-C motif) ligand 5
CCL4 Chemokine (C-C motif) ligand 4
CCL1 Chemokine (C-C motif) ligand 1
CXCR3 Chemokine (C-X-C motif) receptor 3
IL17AR Interleukin 17A
ACVR1B Activin A receptor, type IB
FLT1 Fms-related tyrosine kinase 1
TNFRSF13C Tumor necrosis factor receptor superfamily, member 13C
BMPR2 Bone morphogenetic protein receptor, type II
IL22 Interleukin 22
OSM Oncostatin M
IL21 Interleukin 21
XCL1 Chemokine (C motif) ligand 1
FLT3LG Fms-related tyrosine kinase 3 ligand
CCL28 Chemokine (C-C motif) ligand 28
XCL2 Chemokine (C motif) ligand 2
TNFSF14 Tumor necrosis factor (ligand) superfamily, member 14
Genes of the HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
pathway are given which were found to be enriched in samples of natalizumab-
treated cells by GSEA pathway annotation. Listed genes exhibited an at least
0.5-fold [log 2] stronger expression in natalizumab-treated than in natalizumab-
untreated cells.
doi:10.1371/journal.pone.0052208.t002
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was prepared from CD4+ T cells grown and (re-) stimulated in the
presence or absence of natalizumab. The Affymetrix expression
analysis revealed only mild changes. Nevertheless, several path-
ways were – positively or negatively – affected, clearly demon-
strating a signaling potential of natalizumab (Table 1). The most
prominently influenced gene encoded IL-2 with an approximately
3.5-fold (linear) upregulation by natalizumab (Figure 1A, B).
Expression differences of immunologically relevant genes became
evident by the Gene Set Enrichment Analysis (GSEA) pathway
annotation (Table 2). Specifically, we observed the enrichment of a
cytokine-cytokine receptor interacting pathway among the ten
most significantly influenced pathways in the group of natalizu-
mab-treated compared to untreated samples.
Natalizumab Enhances IL-2 and Th17-specific
Lymphokines
To analyze the effect of natalizumab on lymphokine expression
more closely, important lymphokines, surface molecules, and the
key regulators of CD4+ T cell differentiation were compared on a
heat map (Figure 2A). The fold change was highest for IL-2, but
other lymphokines were also positively influenced by natalizumab.
Important in the context of MS, the panel of Th17-specific
lymphokines was upregulated, whereas the inhibitory lymphokine
IL-10 was repressed by natalizumab. RNA for the homing
receptor of Th17, CCR6, was enhanced. Enrichment could also
be detected for FOXP3, which is the key transcription factor in
regulatory T cells, but also indicative of activation in human
effector T cells [33]. RNA levels of the transcriptional key
regulators of Th17 and Th1 cells, transcribed from RORC and
TBX21, respectively, were upregulated through engagement of
integrin a-4 by natalizumab. The differences in RNA expression
were validated by qRT-PCR with the donors’ RNA samples used
for the microarrays. Moderately increased expression of IL-2 and
of all three tested key transcription factors under the influence of
natalizumab was noted in all specimens from all 3 donors in this
exploratory analysis (Figure 2B). Differences in the levels of
transcription factor specific RNA turned out to be inter-
individually regulated, when analyzing 8 additional donors under
slightly altered experimental conditions. However, using a multiple
comparison test plus Bonferroni correction for testing of 4 targets,
mRNA for FOXP3 was enhanced by natalizumab with high
significance, strongly supporting the notion of natalizumab to
possess signaling capacities (Figure 2C).
Figure 2. Natalizumab supports a pro-inflammatory gene expression profile. (A) RNA expression differences of three independent
biological replicates are depicted in heat maps for immunologically relevant genes. Cells had not or had been restimulated with T/I (TI). Both groups
had been grown with or without natalizumab (N or Nat). (B) qRT-PCR of RNA used for the microarray (triplicates) was analyzed for RNA levels of IL-2 as
well as RORct, T-BET and FOXP3. These three transcription factors are transcribed from the genes RORC, TBX21 and FOXP3, respectively. (C)
Independent replication of the qRT-PCR results in 8 different additional donors. Here, CD4+ T cells were stimulated by anti-CD3/28-DynabeadsH for 10
days and restimulated with T/I for 8 h. Dots represent single donors, lines connect intraindividual values. Friedman tests followed by Dunn’s post
tests were performed in (B) and (C).
doi:10.1371/journal.pone.0052208.g002
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Natalizumab Exerts a Specific Direct Signaling Effect
If natalizumab exerts a direct signaling effect, an influence
should become detectable within the time frame of one cell cycle.
And indeed, intracellular staining for IL-2 and concomitant FACS
analyses demonstrated that CD4+ T cells stimulated with
superantigen (SEB) or anti-CD3/28 for only 24 h both expressed
significantly more IL-2 in the presence of natalizumab (Figure 3A,
B).
In addition to IL-2, expression of IL-17 and IFN-c under the
influence of natalizumab was analyzed on the protein level. In
order to achieve sufficient effector lymphokine expression, CD4+
T cells were activated with the chemical compounds TPA and
ionomycin, bypassing, but mimicking TCR crosslinking by
activating protein kinase C and Ca2+/calcineurin, respectively,
for only 24 h. Intracellular FACS staining revealed robust IL-2
expression after T/I stimulation (median 45.6% CD49dhi cells
without presence of natalizumab), which was more than ten times
higher than that mediated by SEB (median 3.2%) or anti-CD3/28
(median 4.0%) stimulation (Figure 3C). Natalizumab induced a
significant alteration of cytokine levels with both of the weaker
stimuli (Figure 3B), while no significant alteration was observed
with T/I stimulation (Figure 3C). On the other hand, stimulation
with ionomycin alone (median 1.2% CD49dhi cells), which mimics
a solely TCR crosslinking mediated Ca+ influx, although the levels
of IL-2 and IL-17 were not significantly altered, allowed to detect a
significant upregulation of IFN-c expression (Figure 3D). Togeth-
er, these data demonstrated a direct costimulatory potential of
natalizumab via integrin a-4, which became obvious under
conditions mimicking physiological T cell activation.
Natalizumab Supports ERK Phosphorylation
If integrin a-4 can be triggered by natalizumab, footmarks of
the induced signaling should be detectable. For molecular
analyses, we initially used the human CD4+ T cell line Jurkat.
Surface expression of integrin a-4 (Figure 4A) and a positive
influence of natalizumab on IL-2 expression was verified for Jurkat
T cells (Figure 4B). IL-2 and most other lymphokines are
transcribed in dependency of NFAT activation, which is
downstream of Ca2+/calcineurin signals and indicated by its
translocation to the nucleus. Accordingly, we found an enrichment
of the C3 motif gene set NFAT when we annotated the genes that
were found to be upregulated ($0.5 [log2]) in natalizumab-treated
CD4+ T cells using GSEA. However, when NFAT activation was
evaluated, no increased nuclear translocation under the influence
of natalizumab could be observed (Figure 4C).
Thereafter, we analyzed MAPK pathways described to be
touched by integrin signals. Jurkat T cells were stimulated by TPA
and/or ionomycin. (i) While the overall expression of ERK was
unchanged during natalizumab treatment (Figure 4D, lowest
panel), phosphorylation could be rapidly enhanced by natalizu-
mab during stimulation with either TPA or the combined action of
T/I (Figure 4D, both upper panels). (ii) Phosphorylation of JNKs
was supported by natalizumab in TPA-treated Jurkat T cells
(Figure 4E), while any change in phosphorylation of p38 MAPK
could not be detected (data not shown). In primary CD4+ T cells,
the costimulatory effect of natalizumab for TCR crosslinking could
be verified for ERK phosphorylation (Figure 4F), while it was
Figure 3. Intracellular protein levels of IL-2, IL-17 and IFN-c are
enhanced by concomitant treatment with natalizumab. (A, B)
PBMC were stimulated by SEB or anti-CD3/28 without or in the
presence of natalizumab for 24 h. After surface staining for CD4 and
intracellular staining for IL-2, cells were analyzed by FACS. (A)
Representative dot blots are given. (B) Single values of samples from
n=11 (SEB) and n= 17 (anti-CD3/28) donors are shown. (C, D) Isolated
CD4+ T cells were stimulated with T/I (n = 9) or ionomycin (n = 10) for
8 h. Intracellular FACS stainings for IL-2, IL-17, and IFN-c were
performed, and the differences between cultures with and without
natalizumab were calculated. Two-tailed Wilcoxon matched-pairs
signed rank tests were performed for statistical analysis in (B, C, and D).
doi:10.1371/journal.pone.0052208.g003
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Figure 4. Natalizumab signals via rapid phosphorylation of ERK. (A) Surface expression of CD49d was verified for Jurkat cells. (B) Intracellular
FACS staining for IL-2 revealed increased expression in the presence of natalizumab, when cells were stimulated by T/I (2 concentrations) for 8 h. (C)
Western blot analysis of nuclear extracts for NFATc1 after stimulation as indicated for 2 h. (D, E) Immunoblot of proteins extracted from Jurkat cells
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barely detectable for JNK phosphorylation (data not shown).
Unexpectedly, natalizumab even provided a better costimulatory
signal than an agonistic anti-CD49d (clone HP2/1) antibody.
Taken together, natalizumab’s signaling capacity resembled
features of natural integrin signaling.
Natalizumab-induced Reduction of CD49d Surface
Expression Depends on T Cell Activation State
A common feature of receptor engagement and signaling is the
concomitant internalization. We sought to follow integrin a-4
expression on the surface of Jurkat T cells when solely natalizumab
was added. Clearly, CD49d was reduced by the magnitude of
roughly half a log scale within 24 h (Figure 5A). This was not due
to competitive binding of natalizumab and the anti-CD49d
antibody for FACS staining (Figure 5B). When CD4+ T cells
were tested for their pattern of CD49d expression, three
populations, with low, intermediate or high CD49d density, could
be observed (Figure 5C).
Activation of T cells by T/I for 8 h (without natalizumab)
strongly reduced the amount of CD49dhi CD4+ T cells in 4 of 6
samples from independent donors in comparison to unstimulated
cells (median 69.6% reduction, Figure 5D, left upper diagram).
However, when natalizumab was given in addition, the ratio of
CD49dhi CD4+ T cells in +natalizumab vs. –natalizumab samples
tended to decrease more rapidly and more pronounced with no
further stimulation besides natalizumab addition (Figure 5D, right
column). Nevertheless, both resting and T/I-activated T cells
showed a significant relative reduction of CD49dhi populations 8 h
after natalizumab addition. Percentages of CD49dhi cells were
lower among all CD4+ T cells when treated with natalizumab
(+T/I, median 7.3 vs. –T/I; 12.9%, Figure 5D, left lower
diagram).
When comparing CD3/28- and T/I-stimulated cells over a
longer period of time, the relative reduction of CD49hi T cells due
to natalizumab treatment over 24 h was much more pronounced
after activation by CD3/28 costimulation vs. T/I treatment in this
independent set of samples (Mann-Whitney p,0.0001, Figure 5E,
compare first columns of upper and middle panel), while the
percentage of CD49dhi cells among all CD4+ cells did not differ
between natalizumab-treated CD3/28- vs. T/I-activated cells
(Figure 5E, lowest panel). We furthermore demonstrated that
natalizumab-induced CD49d reduction was sustained and did not
tend to increase over 72 h of CD3/28 activation (Figure 5E, upper
panel).
Under all conditions, the CD49dhi population was predomi-
nantly reduced upon natalizumab addition. Major IL-2 correlated
with CD49dhi expression and was only forced into low and
intermediate integrin a-4 expressers by natalizumab (Figure 5F).
Of note, the CD49dhi population produced IFN-c and IL-17 as
well (Figure 5G).
Integrin a-4 is Rapidly Internalized and Degraded Upon
Natalizumab Engagement
We next sought to further investigate the fate of integrin a-4
after natalizumab binding. Immunocytochemical staining of
CD49d in unstimulated PBMC allowed distinction of different
lymphocyte subpopulations according to differential integrin a-4
expression levels, as observed by flow cytometry. CD49d mostly
showed a fine granular pattern of membrane staining, with only
minor intracellular staining observed under a confocal microscope
(Figure 6A). Within 24 h, natalizumab induced a marked
reduction of CD49d surface expression. Here, single cells showed
CD49d-positive, speckled intracellular inclusions, while overall
CD49d surface staining was clearly reduced. Examples of
intracellular inclusions are shown in Figure 6B. In contrast,
isotype control stimulations with IgG4k did not show an effect on
overall CD49d expression levels or subcelluar localization (Figure 6
C).
As only single cells displayed intracellular inclusions after only
24 h of natalizumab stimulation, while the vast majority of cells
showed very low CD49d expression levels, we next evaluated
potential CD49d secretion into cell culture supernatants. Of note,
some members of the integrin family were described to be subject
to shedding from the cell surface by metalloproteinases [34], and
VLA-4 was recently discovered to be a docking site for
matrixmetalloproteinase-9 (MMP-9) in leukemic albeit not in
normal B cells [35]. Employing filter centrifugation for protein
enrichment of PBMC culture supernatants and two different
antibodies against the extracellular domain of CD49d, we were
not able to detect CD49d or its potential fragments by Western
blotting. For this, samples from 4 different donors had been tested
in all combinations of CD3/28 and natalizumab stimulation for
24 h (data not shown). To corroborate this negative finding, we
determined protein levels of MMP-2 and MMP-9 in PBMC
culture supernatants. Surprisingly, natalizumab induced a modest
reduction of MMP-2 secretion, as did CD3/28 costimulation in a
synergistic manner (p,0.05), and it showed a trend towards a
reduction of MMP-9 protein secretion, which in contrast to MMP-
2 was strongly induced by CD3/28. Regarding the fate of CD49d
after natalizumab binding, this set of experiments indicated rapid
intracellular degradation upon internalization.
Natalizumab Treatment Gives Rise to Immediate
Upregulation of IL-2, IFN-c and IL-17 in Some MS Patients
Although primary CD4+ T cells had been analyzed during the
course of the experiments, it was not clear if autoimmune-active
cells would react the same way. Therefore, PBMC were isolated
from 9 RRMS patients immediately before and 24 h after the very
first receipt of natalizumab. To avoid any perturbing influence
from separation procedures, no CD4+ T cell isolation was
performed. PBMC from both blood withdrawals were immedi-
ately analyzed or gently stimulated by plate-bound anti-CD3/28
for 24 h without any further addition of natalizumab. Therefore,
any difference observed can be attributed to the infused drug.
In accordance with the findings in CD4+ T cells from healthy
donors, which were loaded with natalizumab in vitro, PBMC from
MS patients partially lost CD49d/VLA-4 integrin from their
surface within 24 h after infusion. Consistent with the in vitro
experiments using Jurkat and CD4+ T cells from healthy donors,
(re-) stimulation engaging the TCR and costimuli led to a marked
reduction of surface CD49d, which was even more pronounced
after the patients had received natalizumab (Figure 7A). Further-
more, intracellular staining revealed an increase of IL-2, IL-17 and
IFN-c in some of the patients within this short period of treatment
with natalizumab. Due to inter-individual variability, however, it
did not reach statistical significance in the cohort as a whole when
after stimulation with TPA, ionomycin or both in the presence or absence of natalizumab for 2 h. (D) Detection of pERK and ERK within whole cell
extracts. (E) Detection of pJNK and JNK within whole cell extracts. (F) Immunoblot of total proteins extracted from human CD4+ T cells after
stimulation with anti-CD3/28– alone or in combination - in the absence or presence of either agonistic anti-CD49d or natalizumab for 2 h.
Phosphorylated ERK and total ERK were detected.
doi:10.1371/journal.pone.0052208.g004
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each of the individual cytokines was evaluated. Of interest, IL-2
and IL-17 positive cell counts rose in those patients who had
higher positive cell numbers at baseline, possibly corresponding to
stronger Th17 activation before starting natalizumab therapy. The
Figure 5. Natalizumab reduces CD49d surface expression. (A) Jurkat cells were treated with natalizumab for 24 h and stained for CD49d
expression. (B) A possible interference of natalizumab and the staining antibody for CD49d was evaluated. (C) T/I-activated PBMC incubated with
natalizumab for 24 h prior to staining and FACS analyses. Gated on CD4+ T cells, CD49d appeared in three subpopulations. (D) Percentage of CD49dhi
cells among all CD4+ cells after stimulation as indicated for 8 h (left column) and normalization of natalizumab-stimulated to natalizumab-
unstimulated cells without and with T/I activation for 2, 4 and 8 h (right column). CD49dhi expression was evaluated by FACS. (E) CD4+ T cells were
activated with CD3/28 or T/I in the absence or presence of natalizumab for the indicated durations. Ratios of natalizumab-stimulated vs. unstimulated
cells were calculated (upper two diagrams). Lower diagram shows percentage of CD49dhi cells among all CD4+ cells after activation with CD3/28 or T/
I for 24 h. Same samples as in first columns of upper and middle diagram. (F) CD4+ T cells had been preincubated for 24 h with natalizumab, finally
stimulated by T/I for 8 h, stained for CD49d surface and IL-2 intracellular expression and evaluated by FACS. (G) CD4+ T cells were stimulated by T/I for
8 h and stained for intracellular IL-17 and IFN-c as well as for surface expression of CD49d, analyzed by FACS.
doi:10.1371/journal.pone.0052208.g005
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opposite was observed for IFN-c/Th1: low pre-treatment cell
numbers were increased, while higher numbers were decreased by
natalizumab (Figure 7B). Spearman analysis demonstrated a
strong intra-individual correlation between IL-2 and IL-17
induction (R= 0.765) after natalizumab infusion, while no
significant correlation between these two cytokines and IFN-c
was observed (Figure 7C). This argued for a defined direct
natalizumab effect on cytokine secretion in a subset of patients.
Cytometric bead arrays were performed with some of the samples.
Results demonstrated enhanced secretion of IL-2 (2-fold) and IFN-
c (3-fold) after 48 h of in vitro restimulation with anti-CD3/28 in
the majority of tested patients. IL-17 and IL-21 concentrations
were too low to detect, as IL-4 and IL-10 levels were unchanged.
Interestingly, however, IL-12/IL-23 p40 clearly exhibited fortified
secretion when blood was drawn from natalizumab-infused
patients, suggesting an additional, but indirect effect of natalizu-
mab on CD4+ T cells to express IFN-c and IL-17 (Figure 7D). In
conclusion, CD4+ T cells from a subset of MS patients newly
starting natalizumab treatment appeared to exhibit a drug-
induced pro-inflammatory phenotype within the first 24 h after
treatment initiation.
Discussion
Natalizumab blocks the firm arrest of leukocytes to the
endothelium of the BBB, preventing their extravasation into the
CNS with high efficacy. Here we demonstrate that this mAb –
named TysabriH as a drug – additionally has a direct costimulatory
effect on T cells, mildly supporting a pro-inflammatory phenotype.
This was not only shown in vitro with CD4+ T cells from healthy
donors, but also evident in the peripheral blood of MS patients
within 24 h after the very first infusion of natalizumab.
Natalizumab exerts its leukocyte adhesion blocking effect by
direct molecular interference with the binding of VLA-4 on
leukocytes to VCAM-1 on CNS microvascular endothelium. In
addition, integrin a-4 was found to be partially but persistently
downregulated on PBMC of MS patients receiving the drug,
potentially representing an additional mechanism of adhesion
Figure 6. Integrin a-4 is subject to rapid internalization and degradation upon natalizumab binding. (A–C) Immunocytochemical
staining of CD49d and counter-staining of nuclei in PBMC that were either left untreated (A), stimulated with 30 mg/ml natalizumab for 24 h (B) or
stimulated with 30 mg/ml IgG4k isotype control (C). Cells were fixed with 3.7% PFA and permeabilized with 0.1% Triton X-100 before staining.
Representative of samples from 4 different donors. (D) PBMC were stimulated with anti-CD3/28 and/or natalizumab as indicated for 24 h.
Subsequently, total protein levels of MMP-2 and MMP-9 were determined in cell culture supernatants by commercial ELISA kits. Friedman tests,
followed by Dunn’s post tests were performed for statistical analysis.
doi:10.1371/journal.pone.0052208.g006
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blockade [36,37]. Our data now prove that the downregulation of
CD49d surface expression on T lymphocytes is a direct and rapid
consequence of natalizumab binding. Consistent with another
blocking mAb against VLA-4, which mediated the internalization
of integrin a-4 on rat neutrophils [38], we observed natalizumab
to cause intracellular aggregates of CD49d, while no CD49d was
detected in cell culture supernatants. In agreement, we observed
MMP-2 and MMP-9 being downregulated rather than increased
by natalizumab, excluding shedding of VLA-4 as found for
integrin b2 from macrophages [34]. Therefore, natalizumab
probably causes internalization of VLA-4.
However, extravasation is only one possible process that is
mediated by CD49d and its integrin binding partners b-1 and b-7.
Several cellular events are affected in addition to adhesion and
migration, including cell differentiation, polarization, activation
and survival [8]. Therefore, we explored possible immediate
signaling capabilities of natalizumab, addressing the status of
activation and differentiation of CD4+ T cells in the peripheral
blood, which are excluded from the CNS during natalizumab
treatment. And indeed, we observed natalizumab-mediated
signaling, which mildly raised the levels of pro-inflammatory
lymphokines. Here our finding of CD49d reduction depending on
the degree of T cell activation provides one possible explanation
why natalizumab exerted a stronger relative effect on cytokine
secretion in partially vs. fully activated T cells.
Evidence that integrin a-4/b-1 is involved in priming of naive T
cells has been provided: upon binding of a-4 activating antibodies,
VLA-4 colocalizes with the signaling molecules of the TCR
complex and T cells are shifted towards a Th1-type immune
response [39]. Signaling was suggested, as a-4/b-1 localizes within
Figure 7. Natalizumab influences CD4+ T cells from MS patients immediately after the very first infusion. Pre- and post-natalizumab
blood samples were taken from 9 patients with RRMS. (A-C) PBMC were cultivated with plastic-coated anti-CD3/28 for 24 h. (A) Cells were stained for
surface expression of CD4 and CD49d before and after in vitro restimulation. (B, C) Cells were stained for intracellular IL-2, IL-17 and IFN-c
concomitantly with staining for surface CD4, and analyzed by FACS. (D) as in A-C, but in vitro restimulation for 48 h. Secretion of interleukins was
evaluated by cytometric bead arrays. A two-tailed Kruskal-Wallis test followed by Dunn’s posttest was used in (A) for statistical analysis (no matched
pairs test possible due to one missing value). Two-tailed Wilcoxon matched-pairs signed rank tests were performed for statistical analysis in (B) and
(D). Spearman correlation coefficients were calculated in (C).
doi:10.1371/journal.pone.0052208.g007
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the peripheral supramolecular activation cluster (pSMAC) of
synapses between T cells and dendritic cells/B cells [39]. Because
integrins link the cytoskeleton with the extracellular environment,
engagement of VLA-4 sustains signaling by altering the dynamics
of actin filaments and signaling molecules at the immunological
synapse [40]. However, so far it had not been demonstrated that
also the adhesion-blocking antibody natalizumab acts as a
costimulus for T cells, very much resembling a-4/b-1 activating
signals. Integrin-mediated cellular activities involve the activation
of intracellular signaling pathways associated with focal adhesion
kinase (FAK). FAK directly binds to the cytoplasmic domain of
integrin b-1, but also interacts with CD4 [41]. FAK-mediated
pathways include the activation of ERK, providing survival signals
[42], and while a-4/b-1 costimulation of human T cells was
recently found to enhance ERK phosphorylation as well as IL-2
and IFN-c production [43], we now provide evidence that
natalizumab signals via the same route. Therefore, when antigen
cross-links the TCR this leads to NFAT as well as integrin (‘inside-
out’ signal) activation; then natalizumab supports nuclear AP1
induction via MAPK-signaling. NFAT and AP1 form the crucial
transcription factor complex for lymphokine expression [44].
Depending on the context of activation, i. e. classical costimuation
via CD28 family members and present cytokines as well as possible
former encounters of the T cell, integrin signaling might be
enough to support a pro-inflammatory differentiation of the T cell.
The observed consistent increase in FOXP3 expression probably
reflects activation of human effector T cells, where neither
proliferation nor cytokine production are repressed by FOXP3
[33]. In case FOXP3 regulatory T cells would be induced or
propagated by more IL-2 present [45], they may not be able to
repress rebound disease activity [46].
Prolonged therapeutic CD49d blockade by natalizumab
certainly results in unexpected changes of the immune system.
Enrichment with leukocytes of different origin in the periphery
and mobilization of hematopoietic stem/progenitor cells
[47,48,49], enlargement of circulating TNF-a+, IFN-c+, and IL-
17+ cell numbers [28,29,30,50,51], and altered gene expression
profiles [52] were reported. So far this was interpreted as defective
stem cell homing into the bone marrow and as sequestration of
activated cells in the peripheral circulation. Based on our data it
can be concluded, though, that in addition costimulatory features
mediated by natalizumab support a pro-inflammatory phenotype
in the periphery. These primary signaling events via VLA-4 should
funnel into positive feed-back loops with cross-talks to other cell
types, explaining the robust long-term pro-inflammatory bias
observed [28,29,30]. That Th1 differentiation is a specific feature
of natalizumab was demonstrated by a comparative study with
glatiramer acetate just recently [53].
Overall, this helps to explain a rebound of disease activity
observed in some patients after natalizumab cessation [24,25,26].
One current case report not only clearly indicates that such a
relapse after natalizumab withdrawal can be mortal but addition-
ally that it is primarily mediated by CD4+ T cells [27]. Therefore,
the inter-individually different and less dramatic primary events
detected in this study may initiate a fulminant phenotype laying
ground for severe rebound disease in rare cases.
Furthermore, PML-IRIS in natalizumab-treated patients
[19,20,21,22] might be partially attributable to pro-inflammatory
effects of natalizumab outside the CNS: JC virus-specific T cells
are pre-activated, enlarged in number, and when entering the
CNS not efficiently controllable by regulatory T cells or other
mechanisms. PML-IRIS also occurs in other situations of immune
reconstitution, such as in HIV patients starting highly active anti-
retroviral therapy (HAART). However, while the overall clinical
outcome of HAART-associated IRIS was found to be favourable
in the majority of HIV patients with PML [54], natalizumab-
associated IRIS in MS patients with PML often has a poor
outcome [19,21]. This difference might at least partially be due to
the presence of dysregulated CNS-autoreactive T cells in
natalizumab-treated MS, but not in HIV patients.
Taken together, natalizumab efficiently excludes activated
lymphocytes from the CNS by at least two mechanisms, but the
activated pro-inflammatory situation in the periphery caused by
direct signaling capacities of natalizumab might help to explain
some adverse effects of this treatment. Novel integrin a-4 blocking
pharmacological agents, which are currently in clinical develop-
ment, should be carefully evaluated for their signaling potential.
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